Lisa S. Beavers - Trafalgar IN Thomas F. Bumol - Carmel IN Robert A. Gadski - Indianapolis IN Barbara J. Weigel - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C12N 510 C12N 100 C12N 1500
US Classification:
435 691
Abstract:
The present invention comprises novel recombinant DNA compounds which encode monoclonal antibody KS1/4 and chimeric derivatives of monoclonal antibody KS1/4. Eukaryotic expression vectors have been constructed that comprise novel KS1/4-encoding DNA and drive expression of KS1/4 when transformed into an appropriate host cell. The novel expression vectors can be used to create modified and chimeric derivatives of KS1/4. The recombinant-produced KS1/4, KS1/4 derivatives and KS1/4 chimeras are useful for the diagnosis, prognosis and treatment of disease states including adenocarcinoma.
Chimeric Antibodies Directed Against A Human Glycoprotein Antigen
Lisa S. Beavers - Trafalgar IN Thomas F. Bumol - Carmel IN Robert A. Gadski - Indianapolis IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
C12N 506 C12N 1513 C12N 1585
US Classification:
4352402
Abstract:
The present invention discloses novel chimeric monoclonal antibodies, directed against proteoglycans of human melanoma cells, having antigen-specific variable regions of defined amino acid sequences. DNA constructs for the light and heavy chain variable regions comprising the novel antibodies of the invention are provided. Eukaryotic host cells capable of expression of the chimeric antibodies and comprising the novel chimeric antibody-encoding DNA constructs are also provided.